Skip to content

The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems

Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians

Navigating uncharted waters: Developing a standardized approach for evaluating and implementing biosimilar products at a comprehensive cancer center

Monograph Presentation Checklist

P&T Implementation Checklist

Healthcare system conversion to a biosimilar: Trials and tribulations

Formulary Monograph Services

P&T Committee Drug Evaluation Template

Medication Use Evaluation PowerPoint Template